Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Study protocol

EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients

Authors: Thomas Durand, Sophie Jacob, Laura Lebouil, Hassen Douzane, Philippe Lestaevel, Amithys Rahimian, Dimitri Psimaras, Loïc Feuvret, Delphine Leclercq, Bruno Brochet, Radia Tamarat, Fabien Milliat, Marc Benderitter, Nicolas Vayatis, Georges Noël, Khê Hoang-Xuan, Jean-Yves Delattre, Damien Ricard, Marie-Odile Bernier

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

Radiotherapy is one of the most important treatments of primary and metastatic brain tumors. Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the incidence of this complication is not well established and the risk factors and process are poorly understood. The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations.

Method/Design

The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will be studied to determine its sensibility to detect leukoencephalopathy decrement.

Discussion

With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced complications and their associated risk factors.

Trial Registration

Literature
1.
Verdecchia A, Baili P, Quaglia A, Kunkler I, Ciampichini R, Berrino F, et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health. 2008;18:527–32.PubMedCrossRef
2.
Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374:1639–51.PubMedCrossRef
3.
Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2008;71:64–70.PubMedCrossRef
4.
Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin RC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 2003;55:992–9.PubMedCrossRef
5.
6.
Meyer CA, Rock EP, Fine HA. Refining endpoints in brain tumors clinical trials. J Neurooncol. 2012;108:227–30.CrossRef
7.
Froklage FE, Oosterbaan LJ, Sizoo EM, de Groot M, Bosma I, Sanchez E, et al. Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. J Neurooncol. 2014;116:387–94.PubMedCrossRef
8.
Habets EJJ, Taphoorn MJB, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, et al. Health-related quality-of-life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. J Neurooncol. 2014;116:161–8.PubMedCrossRef
9.
Saad S, Wang TJ. Neurocognitive deficits after radiation therapy for brain malignancies. Am J Clin Oncol. 2014. [Epub ahead of print].
10.
Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–18.PubMedCrossRef
11.
Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J Neurooncol. 2009;95:301–5.PubMedCrossRef
12.
Scoccianti S, Detti B, Cipressi S, Iannalfi A, Franzese C, Biti G. Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol. 2012;108:291–308.PubMedCrossRef
13.
Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361–8.PubMedCrossRef
14.
Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002;59:40–8.PubMedCrossRef
15.
Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long- term survivors with malignant astrocytomas. Ann Neurol. 1990;28:818–22.PubMedCrossRef
16.
Vigliani M, Duyckaerts C, Delattre J. Radiation-induced cognitive dysfunction in adults. In: Vecht C et al., editors. Handbook of clinical neurology. Amsterdam: Elsevier Science; 1997. p. 371–88.
17.
Astrand R, Undén J, Romner B. Clinical use of the calcium-binding S100B protein. Methods Mol Biol. 2013;963:373–84.PubMedCrossRef
18.
Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer’s disease. Arch Neurol. 2002;59:972–6.PubMedCrossRef
19.
Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocysteinemia associated with poor recall in the third national health and nutrition examination survey. Am J Clin Nutr. 2001;73:927–33.PubMed
20.
Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013;14(7):R78.PubMedCentralPubMedCrossRef
21.
Xue S, Cai X, Li W, Zhang Z, Dong W, Hui G. Elevated plasma endothelial microparticules in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;34:174–80.PubMedCrossRef
22.
Ruet A, Deloire MS, Charré-Morin J, Hamel D, Brochet B. A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis. Mult Scler. 2013;19:1665–72.PubMedCrossRef
23.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef
24.
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patient with glioblastoma: a prospective randomized controlled trial. J Clin Oncol. 2004;22:1583–8.PubMedCrossRef
25.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28:1963–72.PubMedCrossRef
26.
Wahlund LO, Barkhof F, Fazekas L, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMedCrossRef
27.
Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36:268–72.PubMedCrossRef
28.
Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A. Biological markers of Alzheimer’s disease and mild cognitive impairment. Curr Alzheimer Res. 2004;1:307–14.PubMedCrossRef
29.
Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, et al. Toward the bloodborne miRNome of human diseases. Nat Methods. 2011;8:841–3.PubMedCrossRef
30.
Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012;72:610–24.PubMedCrossRef
31.
Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012;85:348–54.CrossRef
32.
Peiffer AM, Leyrer CM, Greene-Schloesser DM. Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. Neurology. 2013;80:747–53.PubMedCentralPubMedCrossRef
33.
Moore HC. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology. 2014;28:797–804.PubMed
34.
Hermelink K, Küchenhoff H, Untch M, Bauerfeind I, Lux MP, Bühner M, et al. Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010;19:1321–8.PubMedCrossRef
35.
Schagen SB, Boogerd W, Muller MJ, Huinink WT, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairments following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008;47:63–70.PubMedCrossRef
36.
Taillia H, Bompaire F, Jacob J, Noël G. Cognitive evaluation during brain radiotherapy in adults: a simple assessment is possible. Cancer Radiother. 2013;17:413–8.PubMedCrossRef
37.
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumors in adults. Lancet. 2012;379:1984–96.PubMedCrossRef
38.
Mackinnon A, Mullingan R. Estimation de l’intelligence prémorbide chez les francophones. Encéphale. 2005;31:31–43.PubMedCrossRef
39.
Kalafat M, Hugonot-Diener L, Poitrenaud J. Standardisation et étalonnage français du “Mini Mental State” (MMS) version GRECO. Rev Neuropsychol. 2003;13:209–36.
40.
Nasreddine Z, Phillips N, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (moca): a brief screening tool for middle cognitive impairment. J Am Ger Soc. 2005;53:695–99.CrossRef
41.
Mattis M. Dementia Rating Scale-2. Lutz: Psychological assessment resource. Inc; 2001.
42.
Van Der Linden M, Coyette F, Poitrenaud J, Kalafat M, Calicis F, Wyns C, et al. L’épreuve du rappel libre/rappel indicé à 16 items (RL/RI-16). L’évaluation des troubles de la mémoire. Marseille: Editions Solal; 2004. p. 85–101.
43.
Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Arch Psychol. 1941;8:286–340.
44.
Wechsler D. Echelle d’intelligence de Wechsler pour adultes – 3e edition ECPA. 2000.
45.
Meulmans T. La batterie GREFEX. In: Fonctions executives et pathologies neurologiques et psychiatriques. Godefroy et GREFEX, éditeurs. Marseille, Solal; 2008. p. 217–29.
46.
Roussel M, Godefroy O. La batterie GREFEX: données normative Godefroy O et GREFEX, éditeurs. Marseille, Solal; 2008. p. 217–29.
47.
Tuillard-Colombo F, Assal G. Boston Naming Test: French-language adaptation and short forms. Eurn Rev Appl Psychol. 1992;42:67–73.
48.
De Renzi E, Faglioni P. Normative data and screening power of a shortened version of the Token Test. Cortex. 1978;14:41–9.PubMedCrossRef
49.
50.
Furher R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Study Depression Scale). Description et traduction de l’échelle d’auto-évaluation. Psychiat Psychobiol. 1989;4:163–66.
51.
Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–9.PubMed
52.
McNair DM, Kahn RJ. Self assessment of cognitive deficit. In: Crook Th. And Coll. Assessment in geriatric psychopharmacology. Mark Powley Associates Ed, New Canaan-Connecticut; 1983. p. 137–43.
53.
Poitrenaud J, Israel L, Barrere H, le Roc’h. Version française de l’échelle de difficulties cognitive de Mac-Nair et Khan. In: de la plainte mnésique à la maladie d’Alzheimer. Michel BF, Derouesne C, Gely-Nargeot MC, Eds. Marseille, Solal; 1997.
54.
Mac Lachlan S, Devins G, Goodwin P. Validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer. 1998;34:510–7.CrossRef
55.
Taphoorn MJ, Claasens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46:1033–40.PubMedCrossRef
56.
Israel L. L’IADL. In: L’évaluation Clinique standardisée en psychitrie (tome 2). Guelfi, Ed. Editions médicales Pierre Fabre, 1996. p. 477–80.
Metadata
Title
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients
Authors
Thomas Durand
Sophie Jacob
Laura Lebouil
Hassen Douzane
Philippe Lestaevel
Amithys Rahimian
Dimitri Psimaras
Loïc Feuvret
Delphine Leclercq
Bruno Brochet
Radia Tamarat
Fabien Milliat
Marc Benderitter
Nicolas Vayatis
Georges Noël
Khê Hoang-Xuan
Jean-Yves Delattre
Damien Ricard
Marie-Odile Bernier
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0519-6

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue

Research article

A novel homozygous MPV17 mutation in two families with axonal sensorimotor polyneuropathy

Case report

Bent spine syndrome as an initial manifestation of late-onset multiple acyl-CoA dehydrogenase deficiency: a case report and literature review

Research article

Intraoperative neuromonitoring for function-guided resection differs for supratentorial motor eloquent gliomas and metastases

Research article

Increased cortical activation upon painful stimulation in fibromyalgia syndrome

Research article

Overview and evaluation of 15 years of Creutzfeldt-Jakob disease surveillance in Belgium, 1998-2012

Study protocol

Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine